OncoSec, 24 North Main Street, Pennington 08534. Daniel O’Connor, CEO. www.oncosec.com.
OncoSec Medical Incorporated, a company developing intratumoral cancer immunotherapies, has appointed Sara M. Bonstein as CFO/COO.
“Sara is a seasoned strategic executive with significant experience in the public biotechnology and pharmaceutical industry,” said Daniel J. O’Connor, CEO OncoSec. “She joins OncoSec at an extremely important time, as we look to achieve several key milestones in the remainder of 2018. Sara has a proven track record of success and I am pleased she chose to join OncoSec.”
Bonstein joined OncoSec from Advaxis, where she served as CFO, secretary, treasurer and executive vice president. Prior to Advaxis, she held key financial leadership positions with Eli Lilly & Company, ImClone Systems and Johnson & Johnson. Bonstein and her new boss share several previous employers: O’Connor was CEO of Advaxis between 2015 and 2017 and previously worked at ImClone.
She holds a bachelor’s in finance from the College of New Jersey and an MBA from Rider.
In a prepared statement, OncoSec said Bonstein will succeed Richard Slansky, CFO, who will “leave to pursue new opportunities.”